Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.46 |
| ▸ | TUBB | P07437 | 4/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.46 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.46 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.46 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.46 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.46 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3445144 | 0.77 | ALOX15 (0.48) | ALOX15ALOX12TRPV1TUBB4ATUBB | |
| SCHEMBL3568122 | 0.73 | TUBB4A (0.60) | ALOX15ALOX12TRPV1TUBB4ATUBB | |
| SCHEMBL28311819 | 0.71 | TRPV1 (0.57) | ALOX15ALOX12TRPV1TUBB4ATUBB | |
| SCHEMBL10068659 | 0.71 | TRPV1 (0.57) | ALOX15ALOX12TRPV1TUBB4ATUBB | |
| SCHEMBL8532510 | 0.71 | ALOX15 (0.62) | ALOX15ALOX12TRPV1TUBB4ATUBB | |
| SCHEMBL11696442 | 0.71 | ALOX15 (0.54) | ALOX15ALOX12TUBB4ATUBBTUBA3C | |
| Alcohol SCHEMBL29288212 | 0.71 | CYP1A2 (0.61) | ALOX15ALOX12TUBB4ATUBBTUBA3C | |
| SCHEMBL30873035 | 0.71 | ALOX15 (0.57) | ALOX15ALOX12TRPV1TUBB4ATUBB | |
| SCHEMBL27182644 | 0.71 | ALOX15 (0.57) | ALOX15ALOX12TRPV1TUBB4ATUBB | |
| SCHEMBL109505 | 0.70 | CYP1A2 (0.65) | ALOX15ALOX12TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816350-B2 | Substituted [1,2,3] triazolo[4,5-D]pyrimidines as cdk inhibitors | INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) | 2010-10-19 | — | — | US | disclosed |
| US-20060035909-A1 | 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035909-A1 | 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout | CDK8, CDK6, CDK1 | ALOX15 1017/4885ALOX12 1219/4885TRPV1 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.